BPIPPNon-competitive GC inhibitor. Also AC inhibitor CAS# 325746-94-9 |
- Imatinib Mesylate (STI571)
Catalog No.:BCC1115
CAS No.:220127-57-1
- Dasatinib (BMS-354825)
Catalog No.:BCC1281
CAS No.:302962-49-8
- Saracatinib (AZD0530)
Catalog No.:BCC1166
CAS No.:379231-04-6
- DPH
Catalog No.:BCC1538
CAS No.:484049-04-9
- Nilotinib monohydrochloride monohydrate
Catalog No.:BCC1801
CAS No.:923288-90-8
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 325746-94-9 | SDF | Download SDF |
| PubChem ID | 4410990 | Appearance | Powder |
| Formula | C22H16BrN3O3 | M.Wt | 450.28 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 2 mM in DMSO | ||
| Chemical Name | 2-(3-bromophenyl)-5,7-dimethyl-5,7,9-triazatetracyclo[8.7.0.03,8.011,16]heptadeca-1(10),3(8),11,13,15-pentaene-4,6,17-trione | ||
| SMILES | CN1C2=C(C(C3=C(N2)C4=CC=CC=C4C3=O)C5=CC(=CC=C5)Br)C(=O)N(C1=O)C | ||
| Standard InChIKey | QSZKQDDYOLAPII-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C22H16BrN3O3/c1-25-20-17(21(28)26(2)22(25)29)15(11-6-5-7-12(23)10-11)16-18(24-20)13-8-3-4-9-14(13)19(16)27/h3-10,15,24H,1-2H3 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Non-competitive guanylyl cyclase (GC) and adenylyl cyclase (AC) inhibitor. Downregulates cAMP and cGMP synthesis, and suppresses cGMP accumulation in a variety of cell lines (IC50 = 3.4 - 11.2 μM). Inhibits GC-stimulated Cl- transport in vitro and suppresses toxin-induced intestinal fluid accumulation in vivo. |
BPIPP Dilution Calculator
BPIPP Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.2208 mL | 11.1042 mL | 22.2084 mL | 44.4168 mL | 55.521 mL |
| 5 mM | 0.4442 mL | 2.2208 mL | 4.4417 mL | 8.8834 mL | 11.1042 mL |
| 10 mM | 0.2221 mL | 1.1104 mL | 2.2208 mL | 4.4417 mL | 5.5521 mL |
| 50 mM | 0.0444 mL | 0.2221 mL | 0.4442 mL | 0.8883 mL | 1.1104 mL |
| 100 mM | 0.0222 mL | 0.111 mL | 0.2221 mL | 0.4442 mL | 0.5552 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Indiplon
Catalog No.:BCC7720
CAS No.:325715-02-4
- Ascleposide E
Catalog No.:BCN5244
CAS No.:325686-49-5
- 1-Oleoyl lysophosphatidic acid sodium salt
Catalog No.:BCC7792
CAS No.:325465-93-8
- ICA 110381
Catalog No.:BCC6338
CAS No.:325457-99-6
- Sulfo-NHS-SS-Biotin
Catalog No.:BCC3580
CAS No.:325143-98-4
- Ergosta-7,22-dien-3-one
Catalog No.:BCN7088
CAS No.:32507-77-0
- Isorhapotogenin
Catalog No.:BCN3383
CAS No.:32507-66-7
- Myricanone
Catalog No.:BCN5243
CAS No.:32492-74-3
- Periplocymarin
Catalog No.:BCN8485
CAS No.:32476-67-8
- T 0156 hydrochloride
Catalog No.:BCC5803
CAS No.:324572-93-2
- 1-Indanamine hydrochloride
Catalog No.:BCC8467
CAS No.:32457-23-1
- NPS-2143 hydrochloride
Catalog No.:BCC1808
CAS No.:324523-20-8
- GRI 977143
Catalog No.:BCC2401
CAS No.:325850-81-5
- Kaempferol 3-neohesperidoside
Catalog No.:BCN5245
CAS No.:32602-81-6
- Oleuropein
Catalog No.:BCN5246
CAS No.:32619-42-4
- Boc-Ser-OH
Catalog No.:BCC3439
CAS No.:3262-72-4
- Fraxamoside
Catalog No.:BCN5247
CAS No.:326594-34-7
- Mesoridazine Besylate
Catalog No.:BCC3975
CAS No.:32672-69-8
- H-Glu(OtBu)-OtBu.HCl
Catalog No.:BCC2934
CAS No.:32677-01-3
- Edpetiline
Catalog No.:BCN6771
CAS No.:32685-93-1
- FAAH inhibitor 1
Catalog No.:BCC4254
CAS No.:326866-17-5
- Shz 1
Catalog No.:BCC6334
CAS No.:326886-05-9
- MHY1485
Catalog No.:BCC6404
CAS No.:326914-06-1
- H-Nle-OH
Catalog No.:BCC3295
CAS No.:327-57-1
Pyridopyrimidine derivatives as inhibitors of cyclic nucleotide synthesis: Application for treatment of diarrhea.[Pubmed:18559851]
Proc Natl Acad Sci U S A. 2008 Jun 17;105(24):8440-5.
Acute secretory diarrhea induced by infection with enterotoxigenic strains of Escherichia coli involves binding of stable toxin (STa) to its receptor on the intestinal brush border, guanylyl cyclase type C (GC-C). Intracellular cGMP is elevated, inducing increase in chloride efflux and subsequent accumulation of fluid in the intestinal lumen. We have screened a library of compounds and identified a pyridopyrimidine derivatives {5-(3-bromophenyl)-1,3-dimethyl-5,11-dihydro-1H-indeno[2',1':5,6]pyrido[2,3-d]pyr imidine-2,4,6-trione; BPIPP} as an inhibitor of GC-C that can suppress STa-stimulated cGMP accumulation by decreasing GC-C activation in intact T84 human colorectal carcinoma cells. BPIPP inhibited stimulation of guanylyl cyclases, including types A and B and soluble isoform in various cells. BPIPP suppressed stimulation of adenylyl cyclase and significantly decreased the activities of adenylyl cyclase toxin of Bordetella pertussis and edema toxin of Bacillus anthracis. The effects of BPIPP on cyclic nucleotide synthesis were observed only in intact cells. The mechanism of BPIPP-dependent inhibition appears to be complex and indirect, possibly associated with phospholipase C and tyrosine-specific phosphorylation. BPIPP inhibited chloride-ion transport stimulated by activation of guanylyl or adenylyl cyclases and suppressed STa-induced fluid accumulation in an in vivo rabbit intestinal loop model. Thus, BPIPP may be a promising lead compound for treatment of diarrhea and other diseases.
